Regenerative medicine as a new therapeutic strategy for lower urinary tract dysfunction

Sumino, Yasuhiro; Mimata, Hiromitsu

doi:10.1111/iju.12137

Cited by 6 publications

(5 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, due to increases in population aging (WHO Report, 1993) and the associated urological problems, the costs of such disorders have been increasing for society. Cell therapy using a patient's own cells might be an important technology for the treatment of SUI in the future (Sumino, 2013). Mesenchymal stem cells (MSCs) are promising cells for such therapies.…”

Section: Regenerative Medicine For Disorders Of the Lower Urinary Tractmentioning

confidence: 99%

Defined serum- and xeno-free cryopreservation of mesenchymal stem cells

et al. 2014

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) have vast potential in cell therapy, and are experimentally used in the clinic. Therefore, it is critical to find a serum- and xeno-free cryopreservation method. The aim of this study was to compare two serum- and xeno-free cryoprotectants for MSCs. Adipose tissue MSCs (Ad-MSCs) and bone marrow MSCs (BM-MSCs) were cryopreserved in two cryoprotectants: the defined serum- and xeno-free STEM-CELLBANKER™ (CB) and 10 % dimethyl sulfoxide (DMSO) in a xeno-free serum replacement cell culture medium and compared to non-cryopreserved MSCs. MSCs cryopreserved in CB or DMSO had similar morphology and surface marker expression compared to their respective non-cryopreserved MSC. Ad-MSCs and BM-MSC in both cryoprotectant media exhibited reduced mean fluorescence intensity (MFI) for CD105, BM-MSCs for CD73 and Ad-MSC increased MFI for HLA class I compared to non-cryopreserved MSCs. Population doubling time of CB cryopreserved and non-cryopreserved Ad-MSCs was similar (38.1 ± 13.6 and 36.8 ± 12.1 h), but somewhat higher when cryopreserved in DMSO (42.2 ± 10.8 h). BM-MSCs had higher population doubling time (CB 47.7 ± 11.4 and DMSO 62.3 ± 32.9 h respectively, p < 0.05) compared to Ad-MSCs. The viability of Ad-MSCs was significantly higher after cryopreservation in CB compared to DMSO (90.4 ± 4.5 % vs. 79.9 ± 3.8 % respectively). Ad-MSCs and BM-MSCs retained their mesodermal differentiation potential when cryopreserved in both cryoprotectants. The characteristics of Ad-MSCs post-thawing are better preserved by CB than by DMSO in serum- and xeno-free medium. Furthermore, Ad-MSCs and BM-MSCs are differently affected by the cryoprotectants, which may have implications for cell therapy.

show abstract

Section: Regenerative Medicine For Disorders Of the Lower Urinary Tractmentioning

confidence: 99%

Defined serum- and xeno-free cryopreservation of mesenchymal stem cells

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Focused on the urinary tract, it has been reported that BMSC contribute to the reconstruction and replacement of the urinary tract tissues in animal models with an injured urinary tract . Actually, BMSC transplanted to the urinary tract differentiated into composed cells of the urethral sphincter and the urinary bladder, and then transplanted BMSC promoted recovery of urinary tract function .…”

Section: Discussionmentioning

confidence: 99%

Contribution of bone marrow‐derived mesenchymal stem cells to the morphological changes in the bladder after partial outlet obstruction: A preliminary study

et al. 2014

View full text Add to dashboard Cite

Abbreviations & AcronymsObjectives: To investigate the contribution of bone marrow-derived mesenchymal stem cells to the changes in bladder morphology in response to partial bladder outlet obstruction. Methods: Allogenic bone marrow cells were transplanted from transgenic rats expressing green fluorescent protein into female Sprague-Dawley rats 1 day after their bone marrowderived mesenchymal stem cells had been destroyed by irradiation. This generated chimeric rats in which green fluorescent protein labeled bone marrow-derived mesenchymal stem cells replaced host bone marrow-derived mesenchymal stem cells. The animals received partial bladder outlet obstruction or sham surgery 6 weeks later. The animals were killed 6 weeks after the surgery, and bladder tissue was prepared for immunofluorescence with antibodies against a urothelium marker (AE1/AE3), a myofibroblast marker (vimentin), a smooth muscle marker and green fluorescent protein.Results: More labeled bone marrow-derived mesenchymal stem cells were found in the partial bladder outlet obstruction group than in the in the sham group. Most bone marrowderived mesenchymal stem cells were present around the basement membrane (laminin) and lamina propria below the urothelium. Bone marrow-derived mesenchymal stem cells were also found in the urothelium layer, and some of them were double-stained with green fluorescent protein and AE1/AE3. Some bone marrow-derived mesenchymal stem cells, which were located in the interstitial tissue, were double-stained with green fluorescent protein and vimentin. Bone marrow-derived mesenchymal stem cells, which migrated into the smooth muscle layer, showed fusiform morphology, and some were double-stained with green fluorescent protein and smooth muscle marker. Conclusions: Bone marrow-derived mesenchymal stem cells home to the partial bladder outlet obstruction bladder, and these cells have the potential to differentiate into the several components of bladder tissue including the urothelium, myofibroblasts and smooth muscle cells. Thus, bone marrow-derived mesenchymal stem cells contribute to the morphological changes of the bladder in response to partial bladder outlet obstruction.

show abstract

“…MRI with a physical labeling method or alone can be applied to assess migration and survival of transplanted stem cells in bladder dysfunction models and prostate cancer. In addition, studies suggest potential efficiency for use on urethral sphincter dysfunction and erectile dysfunction [74][75][76]. Many studies reported the efficacy of using stem cell in treatment of bladder dysfunction.…”

Section: Urinary Systemmentioning

confidence: 99%

Stem Cell Tracing Through MR Molecular Imaging

Yahyapour

Farhood

Graily

et al. 2018

Tissue Eng Regen Med

View full text Add to dashboard Cite

Stem cell therapy opens a new window in medicine to overcome several diseases that remain incurable. It appears such diseases as cardiovascular disorders, brain injury, multiple sclerosis, urinary system diseases, cartilage lesions and diabetes are curable with stem cell transplantation. However, some questions related to stem cell therapy have remained unanswered. Stem cell imaging allows approval of appropriated strategies such as selection of the type and dose of stem cell, and also mode of cell delivery before being tested in clinical trials. MRI as a non-invasive imaging modality provides proper conditions for this aim. So far, different contrast agents such as superparamagnetic or paramagnetic nanoparticles, ultrasmall superparamagnetic nanoparticles, fluorine, gadolinium and some types of reporter genes have been used for imaging of stem cells. The core subject of these studies is to investigate the survival and differentiation of stem cells, contrast agent's toxicity and long term following of transplanted cells. The promising results of in vivo and some clinical trial studies may raise hope for clinical stem cells imaging with MRI.

show abstract

Regenerative medicine as a new therapeutic strategy for lower urinary tract dysfunction

Cited by 6 publications

References 50 publications

Defined serum- and xeno-free cryopreservation of mesenchymal stem cells

Defined serum- and xeno-free cryopreservation of mesenchymal stem cells

Contribution of bone marrow‐derived mesenchymal stem cells to the morphological changes in the bladder after partial outlet obstruction: A preliminary study

Stem Cell Tracing Through MR Molecular Imaging

Contact Info

Product

Resources

About